Key Decisions in HIV Care: Considerations for Long-Acting Injectable PrEP

In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP).

- Listen as he gives his perspectives on:

- The FDA approval of long-acting cabotegravir for PrEP

- Healthcare professionals’ clinical concerns with long-acting injectable antiretroviral therapy

- Considerations for long-acting cabotegravir as PrEP

• Dosing and administration
• Managing missed doses
• Discontinuation
• Delays in HIV diagnoses found in the HPTN 083 study in men

- CDC recommendations for HIV screening while receiving PrEP

Presenter:

Jason Schafer, PharmD, MPH
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania  

Follow along with the slides at: 
https://bit.ly/3wugMOC

See the entire program at: 
https://bit.ly/3q2DlGd

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.